ReviewInternational journal of hematology2015
State-of-the-art acute and chronic GVHD treatment.
Review in International journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Chronic graft versus host disease in upper limb: Calling upper limb rehabilitation specialists for improving outcomes in patients.Clinical hematology international · 2026Pooled it
- Baseline CD4Journal of blood medicine · 2025Trial
- Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.Cancer chemotherapy and pharmacology · 2021Trial
- Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.Blood advances · 2026Article
- Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria.Journal of clinical apheresis · 2025Article
- Prediction of transplant rejection using non-coding RNAs.Molecular biology reports · 2025Review
- Palmitoylethanolamide (PEA) Induces an Increase in Spleen Regulatory T Cells, Reduces CD8Immunology · 2025Article
- Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔHaematologica · 2025Article
- "The microbiome in graft-versus-host disease: a tale of two ecosystems".Journal of translational medicine · 2025Review
- Imaging of acute small bowel pathologies in oncology patients in the ER part II: the role of computed tomography (CT) in detection of treatment-related small bowel complications.Emergency radiology · 2025Review
- Lupus-like manifestations after allogenic hematopoietic stem cell transplantation: a rare case of chronic graft-versus-host disease.Journal of nephrology · 2025Article
- Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.Journal of clinical medicine · 2024Article
- Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.Molecules (Basel, Switzerland) · 2024Article
- Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape.Diagnostics (Basel, Switzerland) · 2024Review
- Hydrogen in Transplantation: Potential Applications and Therapeutic Implications.Biomedicines · 2024Review
- The Role of Extracorporeal Photopheresis in the Management of Graft Versus Host Disease: Narrative Review.ImmunoTargets and therapy · 2024Review
- Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.Frontiers in immunology · 2024Review
- Article
- Protective and pathogenic functions of innate lymphoid cells in transplantation.Clinical and experimental immunology · 2023Review
- Ikaros expression is associated with an increased risk of chronic graft-versus-host disease.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) remains as the major obstacle for successful hematopoietic stem cell transplant (HSCT). Roughly half of the patients undergoing HSCT develop GVHD which requires treatment, and above 10 % of the patient may die because of it. However, GVHD presents with anti-tumor activity, called graft-versus-tumor (GVT) effect, and it carries significant anti-tumor activity, thus suppressing GVHD completely may increase the relapse of original disease. Thus, it is important to control GVHD to the appropriate level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.